Expanding the influence of SNMMI: Johannes Czernin talks with Virginia Pappas, SNMMI CEO, about her career in professional society leadership. .............................................................. Page 1

AI for PET and SPECT: Balaji and colleagues present a survey of state-of-the-art artificial intelligence methods for PET and SPECT image enhancement and identify emerging trends, including likelihood of clinical benefit. .................................................. Page 4

Time to retire PIOPED? Zuckier and Boone review the history and current relevance of clinical practice based on the 1990 Prospective Investigation of Pulmonary Embolism Diagnosis study and call for development of innovative artificial intelligence–powered approaches. ........................................ Page 13

18F-FET PET and MR for glioma: Mauler and colleagues compare the contributions of MR spectroscopic imaging and amino acid PET in improving detection of tumor tissue in untreated patients with suspected glioma. ........................................... Page 22

Pediatric PET/MRI and COVID-19 vaccine: Luthria and colleagues explore the ability of 18F-FDG PET/MRI imaging to reveal thymus activation in addition to local lymph node reactions after COVID-19 vaccination in children with extra-thoracic cancers. ........................................ Page 25

LAG-3 PET for monitoring immunotherapy: Quan and colleagues evaluate a PET approach for assessing immunotherapy response in lung cancer by imaging upregulation of lymphocyte activation gene 3-expressing tumor-infiltrating lymphocytes. ........................................ Page 28

Preclinical evaluation of CCK-2R ligands: Günther and colleagues describe initial basic and murine stability studies with DOTA-MGS5-derived ligands targeting the cholecystokinin-2 receptor and report on proof-of-concept studies with [68Ga]Ga-DOTA-CCK-66 in patients with medullary thyroid cancer. ........................................ Page 33

18F-FAP-74 versus 18F-FDG: Xu and colleagues investigate the diagnostic accuracy of 18F-fibroblast activation protein inhibitor-74 PET/CT in gastric, liver, and pancreatic cancers and compare the results with those from 18F-FDG PET/CT. ........................................ Page 40

68Ga-FAP PET in pancreatic neoplasms: Spiek- ter and colleagues validate fibroblast activation protein as a target for PET imaging by analyzing immunohistochemical FAP expression in low- and high-grade intraductal papillary mucinous neoplasms and pancreatic ductal adenocarcinomas. .......................................................... Page 52


Safety in the VISION dosimetry substudy: Herrmann and colleagues analyze [177Lu]Lu-PSMA-617 renal and multiorgan safety in patients with metastatic castration-resistant prostate cancer in the VISION dosimetry substudy and look at organ-at-risk cumulative absorbed doses predicted from cycle 1 treatment data. ........................................ Page 71

Long-term nephrotoxicity and [177Lu]Lu-PSMA RLT: Steinhefter and colleagues evaluate post-[177Lu]Lu-PSMA estimated glomerular filtration rate dynamics over ≥12 mo in patients with metastatic castration-resistant prostate cancer. ........................................ Page 79

PSMA RLT and renal impairment: Ravi Kumar and Hofmann provide perspective on PSMA radioligand therapy in prostate cancer and on challenges associated with researching long-term safety in patient groups with limited survival and multiple comorbidities. ........................................ Page 85

PSMA PET segmentation versus histopathology: Wang and colleagues assess the accuracy of intraprostatic tumor volume measurements on PSMA-targeted 18F-DCFPyL PET/CT made with various segmentation methods and compare these with histopathologic prostate results. ........................................ Page 87

Real-world validation of PRIMARY score: Emmett and colleagues assess the reproducibility and diagnostic accuracy of the PRIMARY score in a large cohort of patients who underwent multiparametric MRI and [68Ga]Ga-PSMA PET before diagnostic prostate biopsy. ........................................ Page 94

Boronic acid–based FAP radioligands: Poplawski and colleagues detail preclinical development of PNT6555, a boronic acid–based fibroblast activation protein–α-targeted radiotheranostic for imaging and treatment of FAP-positive tumors. ........................................ Page 100

212Pb-pretargeted theranostics for pancreatic cancer: Bauer and colleagues demonstrate the feasibility and safety of pretargeted α-particle therapy with 212Pb in pancreatic ductal adenocarcinoma and discuss dose limitations and potential adverse effects. ........................................ Page 109

68Ga-pentixafor in primary aldosteronism: Ding and colleagues investigate the clinical value of [68Ga]Ga-pentixafor PET/CT in subtype diagnosis of primary aldosteronism patients with adrenal micronodules <1 cm in diameter and compare results with those from routine clinical methods. ........................................ Page 117

QA and RPT dosimetry: Kayal and colleagues from an IAEA research group report on disparities in structured analyses of radiopharmaceutical therapy SPECT/CT images acquired at various sites using the same protocol and software, highlighting the need for quality assurance. ........................................ Page 125

α,β integrin expression after AMI: Nammas and colleagues prospectively evaluate determinants of myocardial uptake of [68Ga]Ga-NODAGA-RGD, a PET tracer targeting α,β integrin, and its associations with left ventricular function in patients after acute myocardial infarction. ........................................ Page 132

Automated cardiac PET MC: Kurokuma and colleagues develop an automated motion correction algorithm for time–activity curves used in compartmental modeling and compare the predictive value of PET myocardial blood flow with and without this correction in coronary artery disease. ........................................ Page 139

18F-FDG PET or MRI for brain age gap: Doering and colleagues compare MRI- and 18F-FDG–derived brain age gap assessments with cognitive performance, neuropathologic burden, and disease progression in normal, cognitively declining, and cognitively impaired individuals. ........................................ Page 147

Baseline PET radiomics in GAINED study: Carlier and colleagues research the potential added value of baseline predictive PET radiomics features in survival of patients in this randomized phase III trial in diffuse large B-cell lymphoma. ........................................ Page 156

Multiple myeloma and [90Y(Tc)Te]Tc-PentixaTec: Eneke and colleagues present a case study of whole-body imaging with this tracer in a patient with relapsed multiple myeloma and discuss its potential as an alternative to C-X-C motif chemokine receptor 4–targeted PET vectors. ........................................ Page 163